Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.76 |
| ▸ | RAB9A | P51151 | 1/20 | 0.76 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | CA1 | P00915 | 6/20 | 0.63 |
| ▸ | CA2 | P00918 | 6/20 | 0.63 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7152391 | 1.00 | NPC1 (0.76) | NPC1RAB9ATSHRCA1CA2 | |
| SCHEMBL7153084 | 1.00 | NPC1 (0.76) | NPC1RAB9ATSHRCA1CA2 | |
| SCHEMBL7151298 | 1.00 | NPC1 (0.76) | NPC1RAB9ATSHRCA1CA2 | |
| SCHEMBL2573474 | 1.00 | NPC1 (0.76) | NPC1RAB9ATSHRCA1CA2 | |
| SCHEMBL7150020 | 1.00 | NPC1 (0.76) | NPC1RAB9ATSHRCA1CA2 | |
| SCHEMBL14478652 | 1.00 | NPC1 (0.76) | NPC1RAB9ATSHRCA1CA2 | |
| SCHEMBL2573470 | 1.00 | NPC1 (0.76) | NPC1RAB9ATSHRCA1CA2 | |
| SCHEMBL14353200 | 1.00 | NPC1 (0.76) | NPC1RAB9ATSHRCA1CA2 | |
| SCHEMBL6045363 | 0.98 | NPC1 (0.74) | NPC1RAB9ATSHRCA1CA2 | |
| SCHEMBL7152297 | 0.98 | NPC1 (0.74) | NPC1RAB9ATSHRCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110028719-A1 | SCREENING METHODS FOR AMYLOID BETA MODULATORS | WARATAH PHARMACEUTICALS INC. (CA) | 2011-02-03 | — | — | US | disclosed |
| US-20110028719-A1 | SCREENING METHODS FOR AMYLOID BETA MODULATORS | WARATAH PHARMACEUTICALS INC. (CA) | 2011-02-03 | — | — | US | disclosed |
| WO-2007134449-A1 | SCREENING METHODS FOR AMYLOID BETA MODULATORS | WARATAH PHARMACEUTICALS INC. (CA) | 2007-11-29 | — | — | WO | disclosed |
| WO-2004037159-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATING FAT METABOLISM | OBETHERAPY BIOTECHNOLOGY (FR) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028719-A1 | SCREENING METHODS FOR AMYLOID BETA MODULATORS | APP, BACE1, IAPP | NPC1 608/4885RAB9A 4198/4885TSHR 4310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.